Morgan Stanley Initiates Coverage On Minimed Group with Overweight Rating, Announces Price Target of $19

Benzinga Newsdesk www.benzinga.com Neutral 71.4%

Neg 0% Neu 71.4% Pos 0%

Morgan Stanley analyst Kallum Titchmarsh initiates coverage on Minimed Group (NASDAQ:MMED) with a Overweight rating and announces Price Target of $19.